3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
To determine whether 3 months' anticoagulation is as good as or better than 6 months' for the treatment of DVT/PE
Deep Vein Thrombosis
Deep Vein Thrombosis With Pulmonary Embolism
Drug: Duration of anticoagulation
Drug: Warfarin duration
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism|
- Death due to DVT/PE
- Failures of resolution, extension or recurrence of DVT and/or PE during and after treatment.
- Number of major haemorrhages.
- Comparison of length of Hospital stay between those given unfractionated heparin and those given low molecular weight heparin.
|Study Start Date:||September 1999|
|Estimated Study Completion Date:||December 2003|
Multi-centre trial involving 46 hospitals in the United Kingdom, with patients entered by 137 Consultant Physicians. Consenting patients were randomised in a central office to either 3 months' or 6 months' anticoagulation. Information on progress of the patients was requested by the co-ordinating office at 3 months, 6 months and 12 months. Outcomes were measured as death from DVT/PE, non-fatal extensions or recurrences of DVT/PE and major haemorrhages during and after anticoagulation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00365950
|Department of Chest Medicine, Llandough Hospital|
|Cardiff, Wales, United Kingdom, CF62 2XX|
|Department of Chest Medicine, Llandough Hospital,|
|Cardiff, Wales, United Kingdom, CF64 2XX|
|Study Chair:||Aziz Sheikh, MD,FRCGP||Research Committee of the British Thoracic Society|